Drug Trial Radar · NCT07897734
TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
188
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2031
Study completion May 2032
Sponsor
- Lead sponsor
- Tango Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Erasca, Inc.
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TNG462-C103 is a Phase 1/2 study to investigate the safety and antitumor activity of vopimetostat (TNG462) combined with ERAS-0015 in patients with MTAP-null pancreatic or MTAP-null non-small cell lung cancer with RAS mutation.
Conditions
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- NSCLC
- RAS Mutation
- MTAP Deletion
- Lung Cancer
- Pancreatic Cancer Metastatic
- Thoracic Cancer
Interventions
vopimetostatDrug
MTA-cooperative PRMT5 inhibitor
ERAS-0015Drug
Pan-RAS molecular glue
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 Maximum Tolerated DoseTime frame: 21 days
- Phase 2 Combination Anti-neoplastic ActivityTime frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.